Pacific Biosciences of California, Inc. (PACB) Fair Value 2026

PACB · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-28, Pacific Biosciences of California, Inc. (PACB) trades at $1.40. QOC: 5.6/10. Value Trap Risk: 46/100 (WARN). 1/13 models active.

Key Facts

Ticker
PACB
Price
$1.40
Quality Score
5.6/10
Value Trap Risk
46/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +15.3% upside with 32% confidence
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give PACB?

1 Intrinsic Value Models vs. Current Price ($1.40)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.61 +15.3%

All Models Active

All 1 models are displayed above.

What Is Pacific Biosciences of California, Inc. (PACB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pacific Biosciences of California, Inc. is potentially undervalued at its current price of $1.40. Based on our 13-model framework, Pacific Biosciences of California, Inc.'s intrinsic value is estimated at a median fair value of $1.61 — representing +15.3% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About PACB?

1 of 13 models are currently active for PACB. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does PACB Rank in Medical Devices?

Among 159 Medical Devices stocks, PACB ranks #109 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Pacific Biosciences of California, Inc.'s positioning within the Medical Devices segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is PACB a Value Trap?

CirclFi's Value Trap algorithm assigns PACB a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Pacific Biosciences of California, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Pacific Biosciences of California, Inc. earns a quality score of 5.6/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PACB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PACB's 1 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pacific Biosciences of California, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

LFWDLifeward Ltd.QOC 5.6COCHEnvoy Medical, Inc.QOC 5.6NNOXNano-X Imaging Ltd.QOC 5.6PLSMPulsenmore Ltd.QOC 5.6QTIQT Imaging Holdings, Inc.QOC 5.6NXLNexalin Technology, Inc.QOC 5.6ALMRAlamar Biosciences, Inc.QOC 3.8INFUInfuSystem Holdings, Inc.QOC 8.1TMCITreace Medical Concepts, Inc.QOC 6.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: LFWD · COCH · NNOX · PLSM · QTI · NXL · ALMR · INFU · TMCI · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to PACB?

6 companies across all industries closest to PACB’s Quality of Company score of 5.6/10.

SCNIScinai Immunotherapeutics Ltd.QOC 5.6RRGBRed Robin Gourmet Burgers, Inc.QOC 5.6ACETAdicet Bio, Inc.QOC 5.6LUCKLucky Strike Entertainment CorporationQOC 5.6BGSFBGSF, Inc.QOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SCNI · RRGB · ACET · LUCK · BGSF · NVDA

Where Does PACB Sit in CirclFi's Medical Devices Rankings?

PACB is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Pacific Biosciences of California, Inc.’s Valuation?

What is Pacific Biosciences of California, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Pacific Biosciences of California, Inc. (PACB). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PACB overvalued or undervalued right now?

At $1.40, 1 of 1 active models suggest PACB may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Pacific Biosciences of California, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.6 mean for PACB?

Pacific Biosciences of California, Inc.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PACB?

CirclFi analyzes PACB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is PACB a value trap in 2026?

Pacific Biosciences of California, Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Pacific Biosciences of California, Inc. (PACB) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PACB/ · Methodology
Primary sources for this PACB valuation

Market data for PACB as of ; valuations recomputed .